TORONTO--(BUSINESS WIRE)--Cybin to Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17th
OTTAWA, Ontario--(BUSINESS WIRE)--Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, announces that it has received approval by the TSX Venture Exchange for the extension of the expiration date of warrants exercisable to purchase 2,029,250 common sha
TORONTO--(BUSINESS WIRE)---- $PINK.V #AI--Perimeter Medical Imaging AI, Inc. (TSX-V: PINK)(OTC: PYNKF)(FSE:4PC) (“Perimeter” or the “Company”), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, today announced that the Company's Chief Executive Officer, Jeremy Sobotta, will participate in a panel at the Lytham Partners Summer 2021 Investor Conference titled “Innovations in Breast Cancer Detection, S
VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced that certain entities owned and/or controlled, directly or indirectly, by Carl Hansen, Ph.D., Cofounder, Chief Executive Officer, and President of AbCellera, and other senior leaders (collectively, the “Selling Shareholders”), have entered into separate share purchase agreements with experienced institutional investors (the “Buyers”), pursuant to which the Buyers purchased an aggregate 11,900,000 common share
TORONTO--(BUSINESS WIRE)-- #BetterOutcomes--According to new research from AlayaCare, while COVID-19 remains the top challenge identified by home-based care operators, more than half of respondents specifically pointed to caregiver shortage and 45 per cent noted employee churn as critical pain points. AlayaLabs, AlayaCare’s data science team, is helping care agencies manage limited personnel resources and identify retention risks so that they can intervene before an employee departs. “Employee churn is a constan
BASEL, Switzerland & SAN DIEGO--(BUSINESS WIRE)--Bright Peak Therapeutics, a biotechnology company developing next-generation cytokine immunotherapies to treat cancer and autoimmune disease, today announced that it raised $107 million in a Series B financing. The round was led by RA Capital, with participation by founding investor Versant Ventures and new investors Fidelity Management & Research Company, Invus, Qatar Investment Authority, funds and accounts managed by BlackRock, Alexandria
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that two abstracts featuring data from the Company’s prophylactic and therapeutic hepatitis B (HBV) candidates have been accepted for presentation at The Digital International Liver Congress™ 2021 (ILC), the Annual Meeting of the European Association for the Study of the Liver (EASL), taking pl
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse Biosciences” or the “Company”), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced the CellFX® System has been approved by Health Canada for a Medical Device License for use in dermatological procedures requiring ablation and resurfacing of the skin for the reduction, removal, and/or clearance of cellular-based benign lesions. Pulse Biosciences will now expan
TORONTO--(BUSINESS WIRE)--Sigma HealthTech (Sigma), a leading provider of healthcare technology solutions, is proud to announce that their product SigMail, an end-to-end encrypted secure messaging platform for healthcare providers, has been selected as a pre-qualified Vendor of Record for Virtual Visits Solutions (Asynchronous) by Canada Health Infoway (Infoway). Infoway, a not-for-profit organization, funded by the federal government to accelerate the development, adoption and effective use of
TORONTO--(BUSINESS WIRE)--NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”), owner and operator of a network of clinics that deliver category-leading treatment for chronic pain, as well as spinal injuries, sports-related injuries, and concussions, today announced a strategic transaction to acquire KumoCare, a virtual care platform to further expand NeuPath’s virtual care and telemedicine offerings. Prior to the pandemic, patients and their physicians alike preferred an in-person car
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)---- $IMV #DeliveryPlatform--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, today announced the appointment of Jeremy R. Graff, Ph.D. as Chief Scientific Officer, effective as of June 14, 2021. Dr. Graff brings over 20 years of experience in preclinical and clinical research and translational analysis for novel immune-activating therapeutics in oncology. “We are thrilled to
BOSTON & OTTAWA, Ontario--(BUSINESS WIRE)--Canada has become a destination for international collaborations and partnerships, as the long-standing reputation for the quality and caliber of research underway in Canadian SMEs, and research institutions drives awareness. “The annual BIO convention is unique in that unlike other traditional trade shows, it is not companies selling products but rather countries, regions, and states competing to attract companies, talent and investment. This is a dif
MONTREAL--(BUSINESS WIRE)-- #AI--My Intelligent Machines (“MIMs”), a leader in artificial intelligence and systems biology, today announced it has received the Company of the Year 2021 Award by Anges Québec, during their 2021 Annual Gathering which brought together virtually close to 175 participants on June 3rd. MIMs especially stood out thanks to the disruptive innovation at the core of its augmented intelligence software solution, supporting R&D activities applied to life sciences. MIMs’ publi
STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces that the Japan Patent Office has officially allowed the patent of Transgene’s oncolytic virus (OV) backbone VVcopTK-RR- that encodes one or more immune checkpoint inhibitor(s) (ICIs). This authorization in Japan follows similar patent grants obtained in several key other geographies including t
BROOMFIELD, Colo.--(BUSINESS WIRE)-- #ADE--Affygility Solutions, a global leader in providing toxicology services, expands offering with health based exposure limits for natural health products
OTTAWA, Ontario--(BUSINESS WIRE)--Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, announces that it will be virtually presenting at the LD Micro Conference on June 10th at 10:30 A.M. Kym Anthony, Avivagen’s C.E.O., will be presenting for the compa
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for VBI-1901, VBI’s cancer vaccine immunotherapeutic candidate for the treatment of recurrent glioblastoma (GBM) patients with first tumor recurrence. Fast Track Designation facilitates the development and expedites
TORONTO--(BUSINESS WIRE)--Teva Canada’s Life Effects website features real-life stories from patients and caregivers about the reality of living with chronic conditions.
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)---- $IMV #Cancer--IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, will hold its 2021 annual and special meeting of shareholders (the "Meeting") by way of a Virtual only meeting on Friday, June 18, 2021 at 11:00 am Eastern Daylight Time We are pleased to announce that the two leading independent proxy advisory firms that pro
TORONTO--(BUSINESS WIRE)--Cybin Launches EMBARK and Co-Sponsors First Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Burnout and Distress
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) is pleased to announce that the eight incumbent directors of the Company were elected at the Company’s annual general meeting (the “Meeting”) held on June 7, 2021. Detailed results of the vote by proxy for the election of directors are provided below: Nominee Votes For (%) Votes Withheld (%) George M. Milne 80.91 19.09 Peter Greenleaf 92.
EXTON, Pa.--(BUSINESS WIRE)-- #MLR1019--Melior Pharmaceuticals Announces Entry Into “Letter-of-Intent” for the Acquisition of Armesocarb by Adhera Therapeutics.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna files for authorization with Health Canada for its COVID-19 vaccine in adolescents.
VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) today presented an analysis of its Phase 3 AURORA 1 study data at the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) 2021 Congress. The presentation follows the recent introduction of new data from an interim analysis of the AURORA 2 continuation study at the European Alliance of Associations for Rheumatology (EULAR)
TORONTO--(BUSINESS WIRE)--Antibe Therapeutics to Present at Upcoming Virtual Investor Conferences
OTTAWA, Ontario--(BUSINESS WIRE)--Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen” or the “Corporation”),a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, thereby supporting general health and performance, announces that it will be requesting approval from the TSX Venture Exchange for the extension of the expiration date of warrants exercisable to purchase 2,029,
CALGARY, Alberta--(BUSINESS WIRE)--Calgary-based Canadian healthcare innovator and biotech company, BioAro Inc. and CardiAI, have launched an on-site COVID-19 rapid-test laboratory service at the Gahcho Kué diamond mine in the Northwest Territories, a joint venture between De Beers Group (the operator) and Mountain Province Diamonds. BioAro Inc. is a medical diagnostics technology company launched by CardiAI that is using the CoviLamp™- PCR test, along with Health Canada approved COVID-19 tests
